| | Other Issues: previous | next | latest | archiveReviews Treatment of Lennox-Gastaut syndrome: overview and recent findings Kenou van Rijckevorsel PMCID: PMC2646636 Gelastic seizures associated with hypothalamic hamartomas. An update in the clinical presentation, diagnosis and treatment José F Téllez-Zenteno, Cesar Serrano-Almeida, and Farzad Moien-Afshari PMCID: PMC2646637 An update on the toxicity of Aβ in Alzheimer’s disease Jürgen Götz, Lars M Ittner, Nicole Schonrock, and Roberto Cappai PMCID: PMC2646638 Current migraine management – patient acceptability and future approaches Arnaud Fumal and Jean Schoenen PMCID: PMC2646639 Treatment options and patient perspectives in the management of fibromyalgia: future trends Kim Lawson PMCID: PMC2646640 An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS) Salvador Harguindey, Gorka Orive, Ramón Cacabelos, Enrique Meléndez Hevia, Ramón Díaz de Otazu, Jose Luis Arranz, and Eduardo Anitua PMCID: PMC2646641 Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature Daniel J Abrams, Donald C Rojas, and David B Arciniegas PMCID: PMC2646642 Neurosurgical strategies for Gilles de la Tourette’s syndrome Karim Mukhida, Matthew Bishop, Murray Hong, and Ivar Mendez PMCID: PMC2646643 Bipolar disorder and neurophysiologic mechanisms Simon M McCrea PMCID: PMC2646644 Prophylaxis of migraine: general principles and patient acceptance Domenico D’Amico and Stewart J Tepper PMCID: PMC2646645 Expert Opinion Duloxetine in the treatment of generalized anxiety disorder Trevor R Norman and James S Olver PMCID: PMC2646646 New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine Bernhard T Baune PMCID: PMC2646647 New treatment options in the management of fibromyalgia: role of pregabalin Grazyna Zareba PMCID: PMC2646648 Mycophenolate mofetil for myasthenia gravis: a clear and present controversy Chad Heatwole and Emma Ciafaloni PMCID: PMC2646649 Pregabalin for the management of partial epilepsy Philippe Ryvlin, Emilio Perucca, and Sylvain Rheims PMCID: PMC2646650 Original Research SPEEDY babies: A putative new behavioral syndrome of unbalanced motor-speech development Marja-Leena Haapanen, Tuomo Aro, and Elina Isotalo PMCID: PMC2646651 Clinical presentation of anxiety among patients with epilepsy M López-Gómez, M Espinola, J Ramirez-Bermudez, I E Martinez-Juarez, and A L Sosa PMCID: PMC2646652 Premorbid intelligence of inpatients with different psychiatric diagnoses does not differ Paolo Stratta, Ilaria Riccardi, Annarita Tomassini, Maria Marronaro, Roberta Pacifico, and Alessandro Rossi PMCID: PMC2646653 Post-traumatic stress, depression, and anxiety in patients with injury-related chronic pain: A pilot study Sofia Åhman and Britt-Marie Stålnacke PMCID: PMC2646654 Methylphenidate modulates activity within cognitive neural networks of patients with post-stroke major depression: A placebo-controlled fMRI study Rajamannar Ramasubbu and Bradley G Goodyear PMCID: PMC2646655 Progression to vascular dementia of patients with mild cognitive impairment: relevance of mild parkinsonian signs Marco Mauri, Simona Corbetta, Cristina Pianezzola, Elena Ambrosoni, Giulio Riboldazzi, and Giorgio Bono PMCID: PMC2646656 Case Reports Mirror movement associated with neural tube defects Yasir Andrabi, Farideh Nejat, Mostafa El Khashab, and Mohammad Reza Ashrafi PMCID: PMC2646657 Continuous decrease in serum brain-derived neurotrophic factor (BDNF) levels in a neuropsychiatric syndrome of systemic lupus erythematosus patient with organic brain changes Atsuko Ikenouchi-Sugita, Reiji Yoshimura, Nobuhisa Ueda, Yuki Kodama, Wakako Umene-Nakano, and Jun Nakamura PMCID: PMC2646658 Erratum Neuropsychiatr Dis Treat. 2008 December; 4(6): 1283. PMCID: PMC2646659 Corrects: Giorgio L Colombo, et al. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat. 2008 October; 4(5): 967–976. |
